Mario C. Raviglione

Prof. Dr. Mario C. Raviglione

Global Health Centre, University of Milan, Milan 20122, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
CSClaudia Stochino
Claudia Stochino
SVSimone Villa
Simone Villa
PZPatrizia Zucchi
Patrizia Zucchi
PPPierpaolo Parravicini
Pierpaolo Parravicini
AGAndrea Gori
Andrea Gori
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
The COVID-19 infection rate was high in patient with active tuberculosis. Major clinical complications were seen only in two patients thus requiring ex novo oxygen supply, one of whom with advanced tuberculosis died. Nasal swab viral clearance was rapid.

14 August 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
SVSimone Villa
Simone Villa
LCLuigi Codecasa
Luigi Codecasa
MFMarino Faccini
Marino Faccini
MPMirella Maria Pontello
Mirella Maria Pontello
MFMaurizio Ferrarese
Maurizio Ferrarese
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
In countries of the European Union, tuberculosis (TB) mainly affects marginalised people, including asylum seekers. Migratory flows from high-incidence countries to Italy have increased up to 2017, posing challenges to the national health system. This study sought to assess TB and latent TB infection (LTBI) prevalence among asylum seekers in Milan during the biennium 2016–2017 and to evaluate interventions in place.A two-level active surveillance and screening system was developed for both TB and LTBI. Asylum seekers underwent an initial screening with a tuberculin skin test (TST) and a questionnaire at the receiving sites. At the Regional TB Reference Centre, those with a positive result underwent chest radiography. People aged <35 years with negative chest radiography results underwent further testing by interferon-γ release assay. If results of the assay were positive, LTBI treatment was offered. TB and LTBI prevalence were compared with literature data.A total of 5324 asylum seekers, mostly young (10–39 years; 98%), male (84%) and from sub-Saharan Africa (69%), were enrolled in the study. 69 active TB cases were diagnosed and 863 LTBI-positive individuals were detected. TB prevalence was high (1236 per 100 000 population) and LTBI prevalence was 28%. Despite losses (41%) during the transition from initial screening sites and the diagnostic centre, a good TB cure rate (84%) and optimal LTBI treatment completion (94%) were achieved.Our study shows that TB incidence is high among asylum seekers in Milan and that well-coordinated screening measures are critical for early diagnosis and treatment. It also proves that rolling out successful at-scale interventions for both prophylaxis and disease management is feasible.

25 August 2022 in Environmental Research
Verified
Journal Article
Open access
AAAntonella Amendola
Antonella Amendola
Marta CanutiMarta Canuti
Marta Canuti
SBSilvia Bianchi
Silvia Bianchi
SKSudhir Kumar
Sudhir Kumar
CFClara Fappani
Clara Fappani
Elisabetta TanziElisabetta Tanzi
Elisabetta Tanzi
As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA from oropharyngeal swabs (N = 148) and urine (N = 141) was screened with four hemi-nested PCRs and molecular evidence for SARS-CoV-2 infection was found in 13 subjects. Two of the positive patients were from the pandemic period (2/12, 16.7%, March 2020–March 2021) and 11 were from the pre-pandemic period (11/44, 25%, August 2019–February 2020). Sera (N = 146) were tested for anti-SARS-CoV-2 IgG, IgM, and IgA antibodies. Five of the RNA-positive individuals also had detectable anti-SARS-CoV-2 antibodies. No strong evidence of infection was found in samples collected between August 2018 and July 2019 from 100 patients. The earliest sample with evidence of SARS-CoV-2 RNA was from September 12, 2019, and the positive patient was also positive for anti-SARS-CoV-2 antibodies (IgG and IgM). Mutations typical of B.1 strains previously reported to have emerged in January 2020 (C3037T, C14408T, and A23403G), were identified in samples collected as early as October 2019 in Lombardy. One of these mutations (C14408T) was also identified among sequences downloaded from public databases that were obtained by others from samples collected in Brazil in November 2019. We conclude that a SARS-CoV-2 progenitor capable of producing a measles-like syndrome may have emerged in late June-late July 2019 and that viruses with mutations characterizing B.1 strain may have been spreading globally before the first Wuhan outbreak. Our findings should be complemented by high-throughput sequencing to obtain additional sequence information. We highlight the importance of retrospective surveillance studies in understanding the early dynamics of COVID-19 spread and we encourage other groups to perform retrospective investigations to seek confirmatory proofs of early SARS-CoV-2 circulation.

1 February 2025
Verified
Book Chapter
Closed access
PDF file
SBSante Leandro Baldi
Sante Leandro Baldi
IBIlaria Bernotti
Ilaria Bernotti
LDLucia Dall’oLio
Lucia Dall’oLio
PPPier Mario Perrone
Pier Mario Perrone
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione

1 August 2021 in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Verified
Journal Article
Open access
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
HRHans L. Rieder
Hans L. Rieder

10 April 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
CLChristian Lienhardt
Christian Lienhardt
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
The World Health Organization (WHO) End Tuberculosis (TB) Strategy has set ambitious targets to reduce 2015 TB incidence and deaths by 80% and 90%, respectively, by the year 2030. Given the current rate of TB incidence decline (about 2% per year annually), reaching these targets will require new transformational tools and innovative ways to deliver them. In addition to improved tests for early and rapid detection of TB and universal drug-susceptibility testing, as well as novel vaccines for improved prevention, better, safer, shorter and more efficacious treatments for all forms of TB are needed. Only a handful of new drugs are currently in phase II or III clinical trials, and a few combination regimens are being tested, mainly for drug-resistant TB. In this article, capitalising on an increasingly rich medicine pipeline and taking advantage of new methodological designs with great potential, the main areas where progress is needed for a transformational improvement of treatment of all forms of TB are described.